-
A novel system for non-invasive measurement of blood levels of glucose Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-04-17 Olivia Tysoe
People with diabetes mellitus rely predominantly on finger pricking to measure blood levels of glucose, which can be onerous. A popular alternative is electrochemical microneedles used in continuous glucose monitors; however, these systems measure glucose levels in the interstitial fluid rather than in the blood directly, which potentially results in inaccurate measurements. A study in Nature Metabolism
-
Targeting the incretin system in obesity and type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-04-17 Saleem Ansari, Bernard Khoo, Tricia Tan
-
Effect of 5:2 Regimens: Energy-Restricted Diet or Low-Volume High-Intensity Interval Training Combined With Resistance Exercise on Glycemic Control and Cardiometabolic Health in Adults With Overweight/Obesity and Type 2 Diabetes—A Three-Arm Randomized Controlled Trial Diabetes Care (IF 16.2) Pub Date : 2024-04-18 Mian Li, Jie Li, Yu Xu, Jinli Gao, Qiuyu Cao, Yi Ding, Zhuojun Xin, Ming Lu, Xiaoting Li, Haihong Song, Jue Shen, Tianzhichao Hou, Ruixin He, Ling Li, Zhiyun Zhao, Min Xu, Jieli Lu, Tiange Wang, Shuangyuan Wang, Hong Lin, Ruizhi Zheng, Jie Zheng, Callum John Baker, Shenghan Lai, Nathan Anthony Johnson, Guang Ning, Stephen Morris Twigg, Weiqing Wang, Yan Liu, Yufang Bi
OBJECTIVE We aimed to examine the effects of a 5:2 regimens diet (2 days per week of energy restriction by formula diet) or an exercise (2 days per week of high-intensity interval training and resistance training) intervention compared with routine lifestyle education (control) on glycemic control and cardiometabolic health among adults with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND
-
Engineering a Pathway to Glucose-Responsive Therapeutics Diabetes (IF 7.7) Pub Date : 2024-04-12 Matthew J. Webber
In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes® Program. Pathway took a multifaceted approach to provide key funding to diabetes researchers in advancing a broad spectrum of research programs centered on all aspects of understanding, managing, and treating diabetes. Herein the personal perspective of a
-
Pharmacological activation of PDC flux reverses lipid-induced inhibition of insulin action in muscle during recovery from exercise Diabetes (IF 7.7) Pub Date : 2024-04-12 Christian S. Carl, Marie M. Jensen, Kim A. Sjøberg, Dumitru Constantin-Teodosiu, Ian R. Hill, Rasmus Kjøbsted, Paul L. Greenhaff, Jørgen F.P. Wojtaszewski, Erik A. Richter, Andreas M. Fritzen, Bente Kiens
Insulin resistance is a risk factor for type 2 diabetes and exercise can improve insulin sensitivity. However, following exercise high circulating fatty acid (FA) levels might counteract this. We hypothesized that such inhibition would be reduced by forcibly increasing carbohydrate oxidation through pharmacological activation of the pyruvate dehydrogenase complex (PDC). Insulin-stimulated glucose uptake
-
The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors Diabetes (IF 7.7) Pub Date : 2024-04-12 Mayumi Yamato, Nao Kato, Ken-ichi Yamada, Toyoshi Inoguchi
The early pathogenetic mechanism of diabetic retinopathy (DR) and its treatment remain unclear. Therefore, we investigated the early pathogenic alterations in DR using streptozotocin-induced diabetic mice and the protective effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors against these alterations. Retinal vascular leakage was assessed by dextran fluorescence angiography. Retinal thickness
-
Depletion of TBC1D4 improves the metabolic exercise response by overcoming genetically induced peripheral insulin resistance Diabetes (IF 7.7) Pub Date : 2024-04-12 Christian Springer, Christian Binsch, Deborah Weide, Laura Toska, Anna Lena Cremer, Heiko Backes, Anna K. Scheel, Lena Espelage, Jörg Kotzka, Sebastian Sill, Anette Kurowski, Daebin Kim, Sandra Karpinski, Theresia M. Schnurr, Torben Hansen, Sonja Hartwig, Stefan Lehr, Sandra Cames, Jens Brüning, Matthias Lienhard, Ralf Herwig, Stefan Börno, Bernd Timmermann, Hadi Al-Hasani, Alexandra Chadt
The RabGTPase-activating protein (RabGAP) TBC1D4 (=AS160) represents a key component in the regulation of glucose transport into skeletal muscle and white adipose tissue (WAT) and is therefore crucial during the development of insulin resistance and type-2 diabetes. Increased daily activity has been shown to be associated with improved postprandial hyperglycemia in allele carriers of a loss-of-function
-
Engineering a Pathway to Glucose-Responsive Therapeutics Diabetes (IF 7.7) Pub Date : 2024-04-11 Matthew J. Webber
In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes® Program. Pathway took a multifaceted approach to provide key funding to diabetes researchers in advancing a broad spectrum of research programs centered on all aspects of understanding, managing, and treating diabetes. Herein the personal perspective of a
-
Genetic subtypes of prediabetes, healthy lifestyle, and risk of type 2 diabetes Diabetes (IF 7.7) Pub Date : 2024-04-11 Yang Li, Guo-Chong Chen, Jee-Young Moon, Rhonda Arthur, Daniela Sotres-Alvarez, Martha L. Daviglus, Amber Pirzada, Josiemer Mattei, Krista M. Perreira, Jerome I. Rotter, Kent D. Taylor, Yii-Der Ida Chen, Sylvia Wassertheil-Smoller, Tao Wang, Thomas E. Rohan, Joel D. Kaufman, Robert Kaplan, Qibin Qi
Prediabetes is a heterogenous metabolic state with various risk for development of type 2 diabetes (T2D). In this study, we used genetic data on 7,227 US Hispanic/Latinos without diabetes from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and 400,149 non-Hispanic whites without diabetes from the UK Biobank (UKBB) to calculate five partitioned polygenetic risk scores (pPRSs) representing
-
Efficient vascular and neural engraftment of stem cell-derived islets Diabetes (IF 7.7) Pub Date : 2024-04-11 Julia Thorngren, Anja Brboric, Svitlana Vasylovska, Daisy Hjelmqvist, Gunilla T Westermark, Jonna Saarimäki-Vire, Jouni Kvist, Diego Balboa, Timo Otonkoski, Per-Ola Carlsson, Joey Lau
Pluripotent stem cell-derived islets (SC-islets) now emerge as a new source for beta-cell replacement therapy. While the function of human islet transplants is hampered by excessive cell death post-transplantation, contributing factors include inflammatory reactions, insufficient revascularization and islet amyloid formation, there is a gap in knowledge on the engraftment process of the SC-islets.
-
Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity Diabetes Care (IF 16.2) Pub Date : 2024-04-09 Angelo Sabag, Matthew N. Ahmadi, Monique E. Francois, Svetlana Postnova, Peter A. Cistulli, Luigi Fontana, Emmanuel Stamatakis
OBJECTIVE To assess the association between timing of aerobic moderate to vigorous physical activity (MVPA) and risk of cardiovascular disease (CVD), microvascular disease (MVD), and all-cause mortality in adults with obesity and a subset with obesity and type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Participants included adults with obesity (BMI ≥30 kg/m2) and a subset of those with T2D from
-
Associations of Dietary Cholesterol Consumption With Incident Diabetes and Cardiovascular Disease: The Role of Genetic Variability in Cholesterol Absorption and Disease Predisposition Diabetes Care (IF 16.2) Pub Date : 2024-04-09 Shuxiao Shi, Ying Dong, Sujing Wang, Xihao Du, Nannan Feng, Lan Xu, Victor W. Zhong
OBJECTIVE Whether genetic susceptibility to disease and dietary cholesterol (DC) absorption contribute to inconsistent associations of DC consumption with diabetes and cardiovascular disease (CVD) remains unclear. RESEARCH DESIGN AND METHODS DC consumption was assessed by repeated 24-h dietary recalls in the UK Biobank. A polygenetic risk score (PRS) for DC absorption was constructed using genetic
-
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-04-08 Ramzi A. Ajjan, Tadej Battelino, Xavier Cos, Stefano Del Prato, Jean-Christophe Philips, Laurent Meyer, Jochen Seufert, Samuel Seidu
-
Metformin acts through appetite-suppressing metabolite: Lac-Phe Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-04-02 Shimona Starling
Metformin is a first-line medication for type 2 diabetes mellitus (T2DM) that acts to reduce blood levels of glucose, food intake and body weight. The mechanisms behind the therapeutic effects of metformin are not completely understood and various modes of action have been proposed. Now, two independent studies published simultaneously in Nature Metabolism point towards a role for an appetite-suppressing
-
Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting Diabetes Care (IF 16.2) Pub Date : 2024-04-03 Thomas Danne, Michael Joubert, Niels Væver Hartvig, Anne Kaas, Nikoline Nygård Knudsen, Julia K. Mader
OBJECTIVE To evaluate the association of insulin injection adherence, smart insulin pen engagement, and glycemic control using real-world data from 16 countries from adults self-administering basal insulin degludec and bolus insulin with a smart insulin pen (NovoPen 6 or NovoPen Echo Plus) alongside continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS Data were aggregated over 14-day periods
-
Erratum. Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE. Diabetes Care 2024;47:556–561 Diabetes Care (IF 16.2) Pub Date : 2024-04-02 Matthew C. Riddle
In the Commentary cited above, the HbA1c value calling for insulin rescue therapy was twice inadvertently given as 7.0%; the correct value of 7.5% is shown in the revised text below.“A final analysis describes the use of rescue therapy with insulin when the originally assigned second-line treatment no longer keeps HbA1c below 7.5% (14).”“It was initiated about halfway through the study to determine
-
Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use Diabetes Care (IF 16.2) Pub Date : 2024-03-29 David B. Sacks, M. Sue Kirkman, Randie R. Little
Hemoglobin A1c (A1C) is widely used for the diagnosis and management of diabetes. Accurate measurement of A1C is necessary for optimal clinical value. Assay standardization has markedly improved the accuracy and consistency of A1C testing. Devices to measure A1C at point of care (POC) are commercially available, allowing rapid results when the patient is seen. In this review, we describe how standardization
-
Role of Cardiorespiratory Fitness and Mitochondrial Oxidative Capacity in Reduced Walk Speed of Older Adults with Diabetes Diabetes (IF 7.7) Pub Date : 2024-03-29 Sofhia V. Ramos, Giovanna Distefano, Li-Yung Lui, Peggy M. Cawthon, Philip Kramer, Ian J. Sipula, Fiona M. Bello, Theresa Mau, Michael J. Jurczak, Anthony J. Molina, Erin E. Kershaw, David J. Marcinek, Eric Shankland, Frederico G.S. Toledo, Anne B. Newman, Russell T. Hepple, Stephen B. Kritchevsky, Bret H. Goodpaster, Steven R. Cummings, Paul M. Coen
Cardiorespiratory fitness and mitochondrial oxidative capacity are associated with reduced walking speed in older adults. The impact of cardiorespiratory fitness and mitochondrial oxidative capacity on walking speed in older adults with diabetes has not been clearly defined. We examined differences in cardiorespiratory fitness and skeletal muscle mitochondrial oxidative capacity between older adults
-
Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications Diabetes Care (IF 16.2) Pub Date : 2024-03-27 Kathryn E. Nagel, Reshma Ramachandran, Kasia J. Lipska
Escalating insulin prices have prompted public scrutiny of the practices of drug manufacturers, pharmacy benefit managers, health insurers, and pharmacies involved in production and distribution of medications. As a result, a series of policies have been proposed or enacted to improve insulin affordability and foster greater equity in access. These policies have implications for other diabetes and
-
Acute Effects of Vibrating Insoles on Dynamic Balance and Gait Quality in Individuals With Diabetic Peripheral Neuropathy: A Randomized Crossover Study Diabetes Care (IF 16.2) Pub Date : 2024-03-27 Giorgio Orlando, Steven Brown, Edward Jude, Frank L. Bowling, Andrew J.M. Boulton, Neil D. Reeves
OBJECTIVE This study investigated the effects of vibrating insoles on dynamic balance and gait quality during level and stair walking and explored the influence of vibration type and frequency in individuals with diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS Twenty-two men with DPN were assessed for gait quality and postural and dynamic balance during walking and stair negotiation
-
Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials Diabetes Care (IF 16.2) Pub Date : 2024-03-26 Francesco Giorgino, Denise R. Franco, Claudia Nicolay, Andrea Hemmingway, Ángel Rodríguez, Russell J. Wiese
OBJECTIVE This post hoc analysis assessed change from baseline to week 52 in glycemic parameters for tirzepatide (5, 10, 15 mg) versus insulin degludec (SURPASS-3 trial) and glargine (SURPASS-4 trial) in people with type 2 diabetes and different baseline glycemic patterns, based on fasting serum glucose (FSG) and postprandial glucose (PPG) values. RESEARCH DESIGN AND METHODS Participant subgroups with
-
Genetic evidence for distinct biological mechanisms that link adiposity to type 2 diabetes: towards precision medicine Diabetes (IF 7.7) Pub Date : 2024-03-26 Angela Abraham, Madeleine Cule, Marjola Thanaj, Nicolas Basty, M. Amin Hashemloo, Elena P. Sorokin, Brandon Whitcher, Stephen Burgess, Jimmy D. Bell, Naveed Sattar, E. Louise Thomas, Hanieh Yaghootkar
We aimed to unravel the mechanisms connecting adiposity to type 2 diabetes. We employed MR-Clust to cluster independent genetic variants associated with body fat percentage (388 variants) and BMI (540 variants) based on their impact on type 2 diabetes. We identified five clusters of adiposity-increasing alleles associated with higher type 2 diabetes risk (unfavorable adiposity) and three clusters associated
-
Adiponectin Reduces Glomerular Endothelial Glycocalyx Disruption and Restores Glomerular Barrier Function in a Mouse Model of Type 2 Diabetes Diabetes (IF 7.7) Pub Date : 2024-03-26 Sarah Fawaz, Aldara Martin Alonso, Yan Qiu, Raina Ramnath, Holly Stowell-Connolly, Monica Gamez, Carl May, Colin Down, Richard J. Coward, Matthew J. Butler, Gavin I. Welsh, Simon C. Satchell, Rebecca R. Foster
Adiponectin has vascular anti-inflammatory and protective effects. Although adiponectin protects against the development of albuminuria, historically, the focus has been on podocyte protection within the glomerular filtration barrier (GFB). The first barrier to albumin in the GFB is the endothelial glycocalyx (eGlx), a surface gel-like barrier covering glomerular endothelial cells (GEnCs). In diabetes
-
Epistasis Between HLA-DRB1*16:02:01 and SLC16A11 T-C-G-T-T Reduces Odds for Type 2 Diabetes in Southwest American Indians Diabetes (IF 7.7) Pub Date : 2024-03-26 Robert C. Williams, Robert L. Hanson, Bjoern Peters, Kendall Kearns, William C. Knowler, Clifton Bogardus, Leslie J. Baier
We sought to identify genetic/immunologic contributors of type 2 diabetes in an indigenous American community by genotyping all study participants for both high resolution HLA-DRB1 alleles and SLC16A11 to test their risk and/or protection for T2D. These genes were selected based on independent reports that HLA-DRB1*16:02:01 is protective for T2D and that SLC16A11 associates with T2D in individuals
-
Diabetes Management in Detention Facilities: A Statement of the American Diabetes Association Diabetes Care (IF 16.2) Pub Date : 2024-03-25 Daniel L. Lorber, Nuha A. ElSayed, Raveendhara R. Bannuru, Viral Shah, Michael Puisis, Jill Crandall, Sarah Fech-Baughman, Barbara Wakeen, Jo Jo Dantone, Robin Hunter-Buskey, Kenneth Moritsugu, Emily Wang, Marisa Desimone, Ruth Weinstock, Aaron Fischer, Jennifer Sherman, Gabe Eber, William Shefelman
This statement provides guidance for diabetes care in detention facilities. It focuses on areas where the processes for delivery of care to people with diabetes in detention facilities may differ from those in the community, and key points are made at the end of each section. Areas of emphasis, which inform multiple aspects discussed in this statement, include 1) timely identification or diagnosis
-
Protein tyrosine phosphatase 1B in metabolic diseases and drug development Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-22 Mirela Delibegović, Sergio Dall’Angelo, Ruta Dekeryte
-
The hypothalamic–pituitary–gonadal axis and the enigma of Alzheimer disease sex differences Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-21 Florent Sauvé, Loïc Kacimi, Vincent Prévot
-
Erratum. Our National Approach to Diabetes. Diabetes Care 2023;46:252–254 Diabetes Care (IF 16.2) Pub Date : 2024-03-22 Robert M. Califf
In the Duality of Interest section of the article cited above, it was incorrectly noted, due to a clerical error prior to manuscript submission, that the author served on the board of directors for the Center for Policy Analysis on Trade and Health (CPATH); the correct institution is the Critical Path Institute (C-Path). The author apologizes for the error. The online version of the article (https://doi
-
Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-21 Robert C. Baxter
-
Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects Diabetes (IF 7.7) Pub Date : 2024-03-21 Xi Chen, Devjit Tripathy, Robert Chilton, Andrea Hansis-Diarte, Marzieh Salehi, Carolina Solis-Herrera, Eugenio Cersosimo, Ralph A DeFronzo
Acute and chronic SGLT-2 inhibition increase endogenous glucose production (EGP). However, the organ - liver versus kidney - responsible for the increase in EGP has not been identified. 20 T2DM and 12 NGT subjects received [3-3H]-glucose infusion (to measure total EGP) in combination with arterial and renal vein catheterization and PAH infusion for determination of renal blood flow. Total EGP, net
-
Sex differences in diabetic kidney disease explained Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-20 Claire Greenhill
Diabetic kidney disease (DKD) is a common complication of diabetes mellitus and can lead to chronic kidney failure. However, prevention and treatment options are fairly limited. In addition, the incidence and rate of progression of DKD is known to differ between male and female patients. To date, the reasons underlying these sex differences have been unclear. A new study, published in Science Translational
-
The Ailing β-Cell in Diabetes: Insights From a Trip to the ER: The 2023 Outstanding Scientific Achievement Award Lecture Diabetes (IF 7.7) Pub Date : 2024-03-20 Carmella Evans-Molina
The synthesis, processing, and secretion of insulin by the pancreatic β-cell is key for the maintenance of systemic metabolic homeostasis, and loss or dysfunction of β-cells underlies the development of both type 1 diabetes (T1D) and type 2 diabetes (T2D). Work in the Evans-Molina laboratory over the past 15 years has pioneered the idea that regulation of calcium dynamics is critical to β-cell biology
-
Response to Comment Letter: Muscle Metabolomics and Exercise Effects on Cardiometabolic Risk Diabetes (IF 7.7) Pub Date : 2024-03-20 Mark W. Pataky, K. Sreekumaran Nair
We appreciate Dr. Astrada’s interest in our recent article (1). Although he raised concern around using BMI as a screening parameter for our study, BMI was not the only “defining parameter” screening criteria in our study. Fasting glucose > 110mg/dL was also a critical exclusion criterion for the study which limits variation in metabolic characteristics in our study cohort. These and other criteria
-
CPT1A Protects Podocytes from Lipotoxicity and Apoptosis In Vitro and Alleviates Diabetic Nephropathy In Vivo Diabetes (IF 7.7) Pub Date : 2024-03-20 Yajuan Xie, Qian Yuan, Ben Tang, Yaru Xie, Yiling Cao, Yang Qiu, Jieyu Zeng, Zhiwen Wang, Hua Su, Chun Zhang
Defective fatty acid oxidation (FAO) has been implicated in diabetic kidney disease (DKD), yet little is known about the role of carnitine palmitoyltransferase-1A (CPT1A), a pivotal rate-limiting enzyme of FAO, in the progression of DKD. Here, we investigate whether CPT1A is a reliable therapeutic target for DKD. We first confirmed the downregulation expression of CPT1A in glomeruli from diabetic patients
-
Comparison of beta-cell function and insulin sensitivity between normal-weight and obese Chinese with young-onset type 2 diabetes Diabetes (IF 7.7) Pub Date : 2024-03-20 Yingnan Fan, Elaine Chow, Cadmon K.P. Lim, Yong Hou, Sandra T.F. Tsoi, Baoqi Fan, Eric S.H. Lau, Alice P.S. Kong, Ronald C.W. Ma, Hongjiang Wu, Juliana C.N. Chan, Andrea O.Y. Luk
Normal-weight individuals with usual-onset type 2 diabetes had reduced beta-cell function and greater insulin sensitivity compared to their obese counterparts. The relative contribution of beta-cell dysfunction and insulin resistance to young-onset type 2 diabetes (YOD) among normal-weight individuals is not well established. In 44 individuals with YOD (24 normal-weight and 20 obese) and 24 healthy
-
Inceptor loss in mice with obesity Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-18 Shimona Starling
Inceptor (encoded by Iir) is a novel receptor that inhibits insulin receptor and insulin-like growth factor signalling. A previous study showed that loss of inceptor from β-cells in lean normoglycaemic mice improved glucose homeostasis. Now, the same group reports findings on inceptor loss in mouse models of obesity. Inceptor is widely expressed in neurons and pan-neuronal Iir deletion in male DIO
-
Metabolic regulation of skeletal cell fate and function Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-18 Steve Stegen, Geert Carmeliet
-
Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark Diabetes Care (IF 16.2) Pub Date : 2024-03-19 Laura L. Määttä, Signe T. Andersen, Tina Parkner, Claus V.B. Hviid, Lasse Bjerg, Mustafa A. Kural, Morten Charles, Esben Søndergaard, Jens Kuhle, Hatice Tankisi, Daniel R. Witte, Troels S. Jensen
OBJECTIVE To investigate the longitudinal development of neurofilament light chain (NfL) levels in type 2 diabetes with and without diabetic polyneuropathy (+/−DPN) and to explore the predictive potential of NfL as a biomarker for DPN. RESEARCH DESIGN AND METHODS We performed retrospective longitudinal case-control analysis of data from 178 participants of the Anglo-Danish-Dutch Study of Intensive
-
Metabolic Fluxes in the Renal Cortex are Dysregulated In Vivo in Response to High-Fat Diet Diabetes (IF 7.7) Pub Date : 2024-03-19 Clinton M. Hasenour, Deveena R. Banerjee, Jamey D. Young
Diabetes and obesity are risk factors for kidney disease. While renal glucose production increases in diabetes, recent data suggest that gluconeogenic and oxidative capacity decline in kidney disease. Thus, metabolic dysregulation caused by diet-induced insulin resistance may sensitize the kidney for a loss in function. Here we examined how diet-induced insulin resistance disrupts mitochondrial metabolic
-
Intermittent fasting improves glucose homeostasis not entirely dependent on caloric restriction in db/db male mice Diabetes (IF 7.7) Pub Date : 2024-03-19 Dinghao Zheng, Xiaosi Hong, Xiaodan He, Jianghong Lin, Shujin Fan, Jinli Wu, Zhuoxian Liang, Sifan Chen, Li Yan, Meng Ren, Wei Wang
Intermittent fasting (IF), which involves prolonged fasting intervals accompanied by caloric restriction, is an effective dietary treatment for obesity and diabetes. Although IF offers many benefits, it is difficult to determine whether these benefits are the consequences of caloric restriction. Every-other-day feeding (EODF) is a commonly used IF research model. This study was designed to identify
-
HLA Class II (DR, DQ, DP) Genes Were Separately Associated With the Progression From Seroconversion to Onset of Type 1 Diabetes Among Participants in Two Diabetes Prevention Trials (DPT-1 and TN07) Diabetes Care (IF 16.2) Pub Date : 2024-03-18 Lue Ping Zhao, George K. Papadopoulos, Jay S. Skyler, Alberto Pugliese, Hemang M. Parikh, William W. Kwok, Terry P. Lybrand, George P. Bondinas, Antonis K. Moustakas, Ruihan Wang, Chul-Woo Pyo, Wyatt C. Nelson, Daniel E. Geraghty, Åke Lernmark
OBJECTIVE To explore associations of HLA class II genes (HLAII) with the progression of islet autoimmunity from asymptomatic to symptomatic type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS Next-generation targeted sequencing was used to genotype eight HLAII genes (DQA1, DQB1, DRB1, DRB3, DRB4, DRB5, DPA1, DPB1) in 1,216 participants from the Diabetes Prevention Trial-1 and Randomized Diabetes Prevention
-
Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes Diabetes Care (IF 16.2) Pub Date : 2024-03-18 Ying Shang, Emilie Toresson Grip, Angelo Modica, Helena Skröder, Oskar Ström, Fady Ntanios, Soffia Gudbjörnsdottir, Hannes Hagström
OBJECTIVE Type 2 diabetes (T2D) increases the risk for major adverse liver outcomes (MALOs), including cirrhosis and its complications. Patients with T2D frequently have other traits of the metabolic syndrome (MetS). It remains uncertain whether there is a synergistic effect of accumulating MetS traits on future MALO risk. RESEARCH DESIGN AND METHODS Patients with T2D without a history of liver disease
-
Genetic evidence of causal relation between intestinal glucose absorption and early postprandial glucose response: a Mendelian randomization study Diabetes (IF 7.7) Pub Date : 2024-03-18 Simon Peschard, Violeta Raverdy, Pierre Bauvin, Rebecca Goutchtat, Veronique Touche, Bruno Derudas, Celine Gheeraert, Julie Dubois-Chevalier, Robert Caiazzo, Gregory Baud, Camille Marciniak, Helene Verkindt, Naima Oukhouya Daoud, Carel W Le Roux, Philippe Lefebvre, Bart Staels, Sophie Lestavel, François Pattou
The post-prandial glucose response is an independent risk factor for type 2 diabetes. Observationally, early glucose response after an oral glucose challenge has been linked to intestinal glucose absorption, largely influenced by the expression of sodium-glucose-co-transporter-1 (SGLT1). This study utilizes Mendelian randomization (MR) to estimate the causal effect of intestinal SGLT1 expression on
-
Risk of diabetic retinopathy according to subtype of type 2 diabetes Diabetes (IF 7.7) Pub Date : 2024-03-18 Frederik N. Pedersen, Lonny Stokholm, Nis Andersen, Jens Andresen, Toke Bek, Javad Hajari, Steffen Heegaard, Kurt Højlund, Ryo Kawasaki, Caroline S. Laugesen, Sören Möller, Katja Schielke, Jens Steen Nielsen, Jacob V. Stidsen, Reimar W. Thomsen, Benjamin Thinggaard, Jakob Grauslund
Type 2 diabetes is a heterogeneous disease that can be subdivided based on beta-cell function and insulin sensitivity. We aimed to investigate the presence, incidence and progression of diabetic retinopathy (DR) according to subtypes of type 2 diabetes. In a national cohort, we identified three subtypes of type 2 diabetes which included classical, hyperinsulinemic and insulinopenic type 2 diabetes
-
The individual response to antibiotics and diet — insights into gut microbial resilience and host metabolism Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-14 Lars M. M. Vliex, John Penders, Arjen Nauta, Erwin G. Zoetendal, Ellen E. Blaak
-
Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial Diabetes Care (IF 16.2) Pub Date : 2024-03-15 Nanna Lind, Merete B. Christensen, Dorte L. Hansen, Kirsten Nørgaard
OBJECTIVE To compare the 12-month effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) in adults with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS This is a single-center, parallel, open-label, randomized controlled trial including adults with inadequately controlled, insulin-treated type 2 diabetes from the outpatient clinic at Steno Diabetes Center
-
Antibodies drive adipose tissue ageing Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-13 Shimona Starling
The mechanisms underlying metabolic decline during ageing are not well understood. A new study in Cell Metabolism identifies IgG antibodies as factors that accumulate in white adipose tissue (WAT) during ageing, driving tissue fibrosis and impaired metabolic health in mice. “Leveraging our understanding of ageing research, we naturally sought to investigate whether interventions targeting ageing could
-
Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study Diabetes Care (IF 16.2) Pub Date : 2024-03-14 Leah E. Cahill, Rachel A. Warren, Allie S. Carew, Andrew P. Levy, John Sapp, Michelle Samuel, Elizabeth Selvin, Samantha K. Lavallée, Neil Poulter, Michel Marre, Stephen Harrap, Giuseppe Mancia, Katie Harris, John Chalmers, Mark Woodward, Eric B. Rimm
OBJECTIVE Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants with the haptoglobin (Hp)2-2 phenotype but not in participants without the Hp2-2 phenotype. It is unknown whether and how these results translate across different demographic/clinical characteristics and treatment strategies. RESEARCH
-
The Difference Between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and Risk of Diabetic Microvascular Complications Among Adults With Diabetes: A Population-Based Cohort Study Diabetes Care (IF 16.2) Pub Date : 2024-03-12 Daijun He, Bixia Gao, Jinwei Wang, Chao Yang, Ming-Hui Zhao, Luxia Zhang
OBJECTIVE The impact of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate (eGFRdiff) on diabetic microvascular complications (DMCs) remains unknown. We investigated the associations of eGFRdiff with overall DMCs and subtypes, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic neuropathy (DN). RESEARCH DESIGN AND METHODS This prospective
-
Impact of Type 2 Diabetes and Glycated Hemoglobin Levels Within the Recommended Target Range on Mortality in Older Adults With Cognitive Impairment Receiving Care at a Memory Clinic: NCGG-STORIES Diabetes Care (IF 16.2) Pub Date : 2024-03-12 Taiki Sugimoto, Takashi Sakurai, Kazuaki Uchida, Yujiro Kuroda, Haruhiko Tokuda, Takuya Omura, Taiji Noguchi, Ayane Komatsu, Takeshi Nakagawa, Kosuke Fujita, Nanae Matsumoto, Rei Ono, Paul K. Crane, Tami Saito
OBJECTIVE To determine the impact of type 2 diabetes and glycated hemoglobin (HbA1c) levels within the recommended target range according to the Japan Diabetes Society/Japan Geriatrics Society Joint Committee on mortality in older adults with cognitive impairment. RESEARCH DESIGN AND METHODS This retrospective cohort study included 1,528 and 468 patients aged ≥65 years without and with type 2 diabetes
-
Gut microbiota–tryptophan metabolism–GLP-1 axis participates in β-cell regeneration induced by dapagliflozin Diabetes (IF 7.7) Pub Date : 2024-03-12 Yafei Jiang, Jin Yang, Li Xia, Tianjiao Wei, Xiaona Cui, Dandan Wang, Zirun Jin, Xiafang Lin, Fei Li, Kun Yang, Shan Lang, Ye Liu, Jing Hang, Zhe Zhang, Tianpei Hong, Rui Wei
Sodium-glucose co-transporter 2 (SGLT2) inhibitor, an efficacious anti-diabetic agent, which has cardiovascular and renal benefits, can promote pancreatic β-cell regeneration in type 2 diabetic mice. However, the underlying mechanism remains unclear. In this study, we aimed to use multi-omics to identify the mediators involved in β-cell regeneration induced by dapagliflozin. We showed that dapagliflozin
-
Polygenic Risk for Type 2 Diabetes in African Americans Diabetes (IF 7.7) Pub Date : 2024-03-12 Marguerite R. Irvin, Tian Ge, Amit Patki, Vinodh Srinivasasainagendra, Nicole D. Armstrong, Brittney Davis, Alana C Jones, Emma Perez, Lauren Stalbow, Matthew Lebo, Eimear Kenny, Ruth J.F. Loos, Maggie C. Y. Ng, Jordan W. Smoller, James B. Meigs, Leslie A. Lange, Elizabeth W. Karlson, Nita A. Limdi, Hemant K. Tiwari
African Americans (AAs) have been underrepresented in polygenic risk score (PRS) studies. Herein, we integrated genome-wide data from multiple observational studies on type 2 diabetes (T2D), encompassing a total of 101,987 AAs, to train and optimize an AA focused T2D PRS (PRSAA), using a Bayesian polygenic modeling method (PRS-CS). We further tested the score in three independent studies with a total
-
Inhibition of HSP20 ameliorates steatotic liver disease by stimulating ERK2-dependent autophagy Diabetes (IF 7.7) Pub Date : 2024-03-11 Yanli Miao, Yi Zhong, Yutian Li, Haojie Qin, Ling Yang, Guojun Cao, Yong Tang, Ting Yu, Di Fan, Yang Lu1, Jiangtong Peng, Kai Huang
Heat shock protein 20 (HSP20) emerges as a novel regulator of autophagy in the heart. Nonetheless, the detailed function of HSP20 in liver and its effect on autophagy remain unknown. Here, we observed that HSP20 expression is increased in liver tissues from mice and patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD)
-
Thyroid-function reference ranges in the diagnosis of thyroid dysfunction in adults Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-08 Salman Razvi
Applying a uniform reference range across all adults for serum levels of thyroid stimulating hormone and thyroid hormones makes establishing a diagnosis of thyroid dysfunction challenging and could lead to potentially unnecessary treatment. For the results of thyroid function tests to be meaningful, the reference ranges should reflect individual variation in thyroid function.
-
Disparities Between Teleretinal Imaging Findings and Patient-Reported Diabetic Retinopathy Status and Follow-Up Eye Care Interval: A 10-Year Prospective Study Diabetes Care (IF 16.2) Pub Date : 2024-03-08 Paolo S. Silva, Jerry D. Cavallerano, Jennifer K. Sun, Ann M. Tolson, Dorothy Tolls, Martin J. Abrahamson, Lloyd M. Aiello, Lloyd Paul Aiello
OBJECTIVE To assess self-reported awareness of diabetic retinopathy (DR) and concordance of eye examination follow-up compared with findings from concurrent retinal images. RESEARCH DESIGN AND METHODS We conducted a prospective observational 10-year study of 26,876 consecutive patients with diabetes who underwent retinal imaging during an endocrinology visit. Awareness and concordance were evaluated
-
Pioneering new frontiers in circadian medicine chronotherapies for cardiovascular health Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-03-08 Ifene David Festus, Jeri Spilberg, Martin E. Young, Sean Cain, Sepideh Khoshnevis, Michael H. Smolensky, Fariya Zaheer, Giannina Descalzi, Tami A. Martino
Cardiovascular disease (CVD) is a global health concern. Circadian medicine improves cardiovascular care by aligning treatments with our body’s daily rhythms and their underlying cellular circadian mechanisms. Time-based therapies, or chronotherapies, show special promise in clinical cardiology. They optimize treatment schedules for better outcomes with fewer side effects by recognizing the profound
-
Undiagnosed type 2 diabetes: an invisible risk factor Lancet Diabetes Endocrinol. (IF 44.5) Pub Date : 2024-03-06 The Lancet Diabetes & Endocrinology
-
Metabolic remodeling in cancer and senescence and its therapeutic implications Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-03-06 Yeonju Kim, Yeji Jang, Mi-Sung Kim, Chanhee Kang
Cellular metabolism is a flexible and plastic network that often dictates physiological and pathological states of the cell, including differentiation, cancer, and aging. Recent advances in cancer metabolism represent a tremendous opportunity to treat cancer by targeting its altered metabolism. Interestingly, despite their stable growth arrest, senescent cells – a critical component of the aging process
-
Itaconate in host inflammation and defense Trends Endocrin. Met. (IF 10.9) Pub Date : 2024-03-05 Dan Ye, Pu Wang, Lei-Lei Chen, Kun-Liang Guan, Yue Xiong
Immune cells undergo rapid and extensive metabolic changes during inflammation. In addition to contributing to energetic and biosynthetic demands, metabolites can also function as signaling molecules. Itaconate (ITA) rapidly accumulates to high levels in myeloid cells under infectious and sterile inflammatory conditions. This metabolite binds to and regulates the function of diverse proteins intracellularly
-
Controlling brown adipose tissue size through EPAC1 Nat. Rev. Endocrinol. (IF 40.5) Pub Date : 2024-03-04 Francesc Villarroya, Marta Giralt